TrialHead & neck2021

Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma.

David M Cognetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.